SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    G. Low, G. J. M. Alexander, D. J. Lomas, Hepatorenal Syndrome: Aetiology, Diagnosis, and Treatment, Gastroenterology Research and Practice, 2015, 2015, 1

    CrossRef

  2. 2
    René Fahrner, Eleonora Patsenker, Andrea de Gottardi, Felix Stickel, Matteo Montani, Deborah Stroka, Daniel Candinas, Guido Beldi, Elevated Liver Regeneration in Response to Pharmacological Reduction of Elevated Portal Venous Pressure by Terlipressin After Partial Hepatectomy, Transplantation, 2014, 97, 9, 892

    CrossRef

  3. 3
    R. Ennaifer, H. Romdhane, R. Hefaiedh, H. Ben Nejma, N. Bel Hadj, Insuffisance rénale aigüe chez le patient cirrhotique : particularités diagnostiques et thérapeutiques, Journal Africain d'Hépato-Gastroentérologie, 2014, 8, 4, 189

    CrossRef

  4. 4
    Achuthan Sourianarayanane, Rupesh Raina, Gaurav Garg, Arthur J. McCullough, Robert S. O’Shea, Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients, International Urology and Nephrology, 2014, 46, 4, 793

    CrossRef

  5. 5
    Richard Moreau, Paracentesis-induced inflammation: a new syndrome?, Liver International, 2014, 34, 7
  6. 6
    Ezequiel Rodríguez, Chiara Elia, Elsa Solà, Rogelio Barreto, Isabel Graupera, Alida Andrealli, Gustavo Pereira, Maria Poca, Jordi Sánchez, Mónica Guevara, Germán Soriano, Carlo Alessandria, Javier Fernández, Vicente Arroyo, Pere Ginès, Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis, Journal of Hepatology, 2014, 60, 5, 955

    CrossRef

  7. 7
    Claudia Fagundes, Rogelio Barreto, Mónica Guevara, Elisabet Garcia, Elsa Solà, Ezequiel Rodríguez, Isabel Graupera, Xavier Ariza, Gustavo Pereira, Ignacio Alfaro, Andrés Cárdenas, Javier Fernández, Esteban Poch, Pere Ginès, A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis, Journal of Hepatology, 2013, 59, 3, 474

    CrossRef

  8. 8
    N. Fayed, E.K. Refaat, T.E. Yassein, M. Alwaraqy, Effect of perioperative terlipressin infusion on systemic, hepatic, and renal hemodynamics during living donor liver transplantation, Journal of Critical Care, 2013, 28, 5, 775

    CrossRef

  9. 9
    Hae Rim Kim, Young Sun Lee, Hyung Joon Yim, Hyun Joo Lee, Ja Young Ryu, Hyun Jung Lee, Eileen L. Yoon, Sun Jae Lee, Jong Jin Hyun, Sung Woo Jung, Ja Seol Koo, Rok Sun Choung, Sang Woo Lee, Jai Hyun Choi, Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome, Clinical and Molecular Hepatology, 2013, 19, 4, 417

    CrossRef

  10. 10
    P. Bellot, B. Martínez-Moreno, J.M. Palazón, J. Duch, Ascitis y síndrome hepatorrenal, Medicine - Programa de Formación Médica Continuada Acreditado, 2012, 11, 11, 644

    CrossRef

  11. 11
    Mu-Huo Ji, Jian-Jun Yang, Jing Wu, Ren-Qi Li, Guo-Min Li, Yun-Xia Fan, Wei-Yan Li, Experimental sepsis in pigs—effects of vasopressin on renal, hepatic, and intestinal dysfunction, Upsala Journal of Medical Sciences, 2012, 117, 3, 257

    CrossRef

  12. 12
    Yoshiyuki Narahara, Hidenori Kanazawa, Choitsu Sakamoto, Hitoshi Maruyama, Osamu Yokosuka, Satoshi Mochida, Masahito Uemura, Hiroshi Fukui, Yasukiyo Sumino, Yasushi Matsuzaki, Naohiko Masaki, Shigehiro Kokubu, Kiwamu Okita, The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study, Journal of Gastroenterology, 2012, 47, 3, 313

    CrossRef

  13. 13
    Hui-Hui Tan, Paul Martin, Care of the Liver Transplant Candidate, Clinics in Liver Disease, 2011, 15, 4, 779

    CrossRef

  14. 14
    James Y. Findlay, Oren K. Fix, Catherine Paugam-Burtz, Linda Liu, Puneet Sood, Stephen J. Tomlanovich, Jean Emond, Critical care of the end-stage liver disease patient awaiting liver transplantation, Liver Transplantation, 2011, 17, 5
  15. 15
    Mortada H.F. El-Shabrawi, Naglaa M. Kamal, Medical Management of Chronic Liver Diseases (CLD) in Children (Part II), Pediatric Drugs, 2011, 13, 6, 371

    CrossRef

  16. 16
    S.K. Sarin, Praveen Sharma, Terlipressin: An Asset for Hepatologists!, Hepatology, 2011, 54, 2
  17. 17
    Basilio Fimiani, Domenico Della Guardia, Claudio Puoti, Giuseppe D' Adamo, Olimpia Cioffi, Anna Pagano, Maria Rosaria Tagliamonte, Antonio Izzi, The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: A multicentric study, European Journal of Internal Medicine, 2011, 22, 6, 587

    CrossRef

  18. 18
    Young Seok Kim, Ascites, Hepatorenal Syndrome and Spontaneous Bacterial Peritonitis in Patients with Portal Hypertension, The Korean Journal of Gastroenterology, 2010, 56, 3, 168

    CrossRef

  19. 19
    EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis, Journal of Hepatology, 2010, 53, 3, 397

    CrossRef

  20. 20
    Aleksander Krag, Søren Møller, Jens H. Henriksen, Flemming Bendtsen, Effects of a single dose of terlipressin on transcutaneous oxygen pressures, Scandinavian Journal of Gastroenterology, 2010, 45, 7-8, 953

    CrossRef

  21. 21
    Aleksander Krag, Flemming Bendtsen, Christian Mortensen, Jens H. Henriksen, Søren Møller, Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis, European Journal of Gastroenterology & Hepatology, 2010, 22, 9, 1085

    CrossRef

  22. 22
    Georgios N. Kalambokis, Konstantinos Pappas, Gerasimos Baltayiannis, Alexandra Katsanou, Epameinondas V. Tsianos, Effects of terlipressin on water excretion after oral water load test in nonazotemic cirrhotic patients with ascites without hyponatremia, Scandinavian Journal of Gastroenterology, 2010, 45, 12, 1509

    CrossRef

  23. 23
    André Nazar, Gustavo Henrique Pereira, Mónica Guevara, Marta Martín-Llahi, Marie-Noëlle Pepin, Marcella Marinelli, Elsa Solá, María Eugenia Baccaro, Carlos Terra, Vicente Arroyo, Pere Ginès, Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome, Hepatology, 2010, 51, 1
  24. 24
    Oh Sang Kwon, Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome, The Korean Journal of Hepatology, 2010, 16, 1, 100

    CrossRef

  25. 25
    Elsa Solà, Pere Ginès, Renal and circulatory dysfunction in cirrhosis: Current management and future perspectives, Journal of Hepatology, 2010, 53, 6, 1135

    CrossRef

  26. 26
    Richard Moreau, François Durand, Renal insufficiency: Management prior to transplantation, Liver Transplantation, 2010, 16, S2
  27. 27
    M.T. Keegan, B. Gali, D.R. Brown, B.A. Harrison, D.J. Plevak, J.Y. Findlay, Serum Vasopressin Concentrations During Orthotopic Liver Transplantation, Transplantation Proceedings, 2010, 42, 7, 2594

    CrossRef

  28. 28
    Christos K. Triantos, Dimitrios Samonakis, Ulrich Thalheimer, Evangelos Cholongitas, Marco Senzolo, Laura Marelli, Gioacchino Leandro, David Patch, Andrew K. Burroughs, Terlipressin therapy for renal failure in cirrhosis, European Journal of Gastroenterology & Hepatology, 2010, 22, 4, 481

    CrossRef

  29. 29
    Pierre Asfar, Peter Radermacher, Paul Calès, Frédéric Oberti, The effects of vasopressin and its analogues on the liver and its disorders in the critically ill, Current Opinion in Critical Care, 2010, 16, 2, 148

    CrossRef

  30. 30
    R. Moreau, C. Francoz, D. Lebrec, F. Durand, Réanimation hépatosplanchnique, 2010,

    CrossRef

  31. 31
    Xiao Xu, Qi Ling, Min Zhang, Feng Gao, Zenglei He, Jingya You, Shusen Zheng, Outcome of Patients With Hepatorenal Syndrome Type 1 After Liver Transplantation: Hangzhou Experience, Transplantation, 2009, 87, 10, 1514

    CrossRef

  32. 32
    Pere Ginès, Robert W. Schrier, Renal Failure in Cirrhosis, New England Journal of Medicine, 2009, 361, 13, 1279

    CrossRef

  33. 33
    Adam G Testro, Peter W Angus, Targeting circulatory dysfunction in cirrhosis: Terlipressin and the hepatorenal syndrome, Journal of Gastroenterology and Hepatology, 2009, 24, 11
  34. 34
    M. Hennenberg, J. Trebicka, A. Z. Kohistani, J. Heller, T. Sauerbruch, Vascular hyporesponsiveness to angiotensin II in rats with CCl4-induced liver cirrhosis, European Journal of Clinical Investigation, 2009, 39, 10
  35. 35
    D. Schneditz, I. Bachler, V. Stadlbauer, R. E. Stauber, Albumin infusion fails to restore circulatory function following paracentesis of tense ascites as assessed by beat-to-beat haemodynamic measurements, International Journal of Clinical Practice, 2008, 62, 12
  36. 36
    R. Gonzlez-Alonso, L. Crespo, X. Garca-Aguilera, A. Albillos Martnez, Ascitis y s?ndrome hepatorrenal en la cirrosis hep?tica, Medicine - Programa de Formaci?n M?dica Continuada Acreditado, 2008, 10, 11, 702

    CrossRef

  37. 37
    R. Moreau, F. Durand, D. Lebrec, L’ascite réfractaire chez les malades atteints de cirrhose, Gastroentérologie Clinique et Biologique, 2008, 32, 8-9, 703

    CrossRef

  38. 38
    Adam G Testro, Sarah Wongseelashote, Peter W Angus, Paul J Gow, Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome, Journal of Gastroenterology and Hepatology, 2008, 23, 10
  39. 39
    P.A. McCormick, Carmel Donnelly, Management of hepatorenal syndrome, Pharmacology & Therapeutics, 2008, 119, 1, 1

    CrossRef

  40. 40
    Paolo Caraceni, Francesca Dazzani, Eugenio Salizzoni, Marco Domenicali, Andrea Zambruni, Franco Trevisani, Mauro Bernardi, Muscle circulation contributes to hyperdynamic circulatory syndrome in advanced cirrhosis, Journal of Hepatology, 2008, 48, 4, 559

    CrossRef

  41. 41
    R. Moreau, D. Lebrec, Physiopathologie et pronostic de l’ascite réfractaire chez les malades atteints de cirrhose, Gastroentérologie Clinique et Biologique, 2008, 32, 8-9, 705

    CrossRef

  42. 42
    R. Moreau, D. Lebrec, Prise en charge de l’ascite réfractaire à l’exclusion de l’anastomose portosystémique intrahépatique et de la transplantation hépatique, Gastroentérologie Clinique et Biologique, 2008, 32, 8-9, 710

    CrossRef

  43. 43
    Stefan Lauer, Fritz Daudel, Daniel L. Traber, Jerzy-Roch Nofer, Christian Ertmer, Andrea Morelli, Hugo Van Aken, Matthias Lange, Sebastian Rehberg, Björn Ellger, Henning D. Stubbe, Claudius Kruse, Hans-Georg Bone, Martin Westphal, SOMATOSTATIN INFUSION INCREASES INTESTINAL ISCHEMIA AND DOES NOT IMPROVE VASOCONSTRICTOR RESPONSE TO NOREPINEPHRINE IN OVINE ENDOTOXEMIA, Shock, 2008, 30, 5, 603

    CrossRef

  44. 44
    Santiago J. Munoz, The Hepatorenal Syndrome, Medical Clinics of North America, 2008, 92, 4, 813

    CrossRef

  45. 45
    F. Bendtsen, A. Krag, S. Møller, Treatment of acute variceal bleeding, Digestive and Liver Disease, 2008, 40, 5, 328

    CrossRef

  46. 46
    Rinaldo Bellomo, Li Wan, Clive May, Vasoactive drugs and acute kidney injury, Critical Care Medicine, 2008, 36, Suppl, S179

    CrossRef

  47. 47
    Georgios N. Kalambokis, Epameinondas V. Tsianos, Vasoconstrictor therapy for patients with cirrhosis with ascites but without hepatorenal syndrome, Hepatology, 2008, 48, 2
  48. 48
    Joseph K. Lim, Roberto J. Groszmann, Vasoconstrictor Therapy for the Hepatorenal Syndrome, Gastroenterology, 2008, 134, 5, 1608

    CrossRef

  49. 49
    Andrés Cárdenas, Pere Ginès, What’s new in the treatment of ascites and spontaneous bacterial peritonitis, Current Gastroenterology Reports, 2008, 10, 1, 7

    CrossRef

  50. 50
    Nick Murphy, Critical Care Medicine, 2008,

    CrossRef

  51. 51
    Marie-Noëlle Pépin, Pere Ginès, Therapy in Nephrology & Hypertension, 2008,

    CrossRef

  52. 52
    Richard Moreau, Didier Lebrec, Diagnosis and treatment of acute renal failure in patients with cirrhosis, Best Practice & Research Clinical Gastroenterology, 2007, 21, 1, 111

    CrossRef

  53. 53
    Georgios Kalambokis, Andreas Fotopoulos, Michalis Economou, Konstantinos Pappas, Epameinondas V. Tsianos, Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites, Journal of Hepatology, 2007, 46, 2, 213

    CrossRef

  54. 54
    Dominique Thabut, Julien Massard, Alice Gangloff, Nicolas Carbonell, Claire Francoz, Eric Nguyen-Khac, Christian Duhamel, Didier Lebrec, Thierry Poynard, Richard Moreau, Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure, Hepatology, 2007, 46, 6
  55. 55
    C. Alessandria, A. Ottobrelli, W. Debernardi-Venon, L. Todros, M. Torrani Cerenzia, S. Martini, F. Balzola, A. Morgando, M. Rizzetto, A. Marzano, Noradrenalin vs terlipressin in patients with hepatorenal syndrome: A prospective, randomized, unblinded, pilot study, Journal of Hepatology, 2007, 47, 4, 499

    CrossRef

  56. 56
    Andres T Blei, Portal hypertension and its complications, Current Opinion in Gastroenterology, 2007, 23, 3, 275

    CrossRef

  57. 57
    J. J. KUIPER, R. A. DE MAN, H. R. VAN BUUREN, Review article: management of ascites and associated complications in patients with cirrhosis, Alimentary Pharmacology & Therapeutics, 2007, 26,
  58. 58
    Pere Ginès, Mónica Guevara, Therapy with vasoconstrictor drugs in cirrhosis: The time has arrived, Hepatology, 2007, 46, 6
  59. 59
    Aleksandra Kezic, Dragana Mijac, Biljana Stojimirovic, Treatment of hepatorenal syndrome, Vojnosanitetski pregled, 2007, 64, 11, 773

    CrossRef

  60. 60
    F. FABRIZI, V. DIXIT, P. MARTIN, Meta-analysis: terlipressin therapy for the hepatorenal syndrome, Alimentary Pharmacology & Therapeutics, 2006, 24, 6
  61. 61
    Richard Moreau, Variceal Bleeding, Infections and the Hepatorenal Syndrome,